JP2024508334A5 - - Google Patents

Info

Publication number
JP2024508334A5
JP2024508334A5 JP2023553354A JP2023553354A JP2024508334A5 JP 2024508334 A5 JP2024508334 A5 JP 2024508334A5 JP 2023553354 A JP2023553354 A JP 2023553354A JP 2023553354 A JP2023553354 A JP 2023553354A JP 2024508334 A5 JP2024508334 A5 JP 2024508334A5
Authority
JP
Japan
Prior art keywords
patient
level
composition according
lomitapide
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/018672 external-priority patent/WO2022187463A1/en
Publication of JP2024508334A publication Critical patent/JP2024508334A/ja
Publication of JP2024508334A5 publication Critical patent/JP2024508334A5/ja
Pending legal-status Critical Current

Links

JP2023553354A 2021-03-03 2022-03-03 家族性高カイロミクロン血症症候群を治療するための方法 Pending JP2024508334A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163155960P 2021-03-03 2021-03-03
US63/155,960 2021-03-03
US202163165457P 2021-03-24 2021-03-24
US63/165,457 2021-03-24
PCT/US2022/018672 WO2022187463A1 (en) 2021-03-03 2022-03-03 Methods for treating familial chylomicronemia syndrome

Publications (2)

Publication Number Publication Date
JP2024508334A JP2024508334A (ja) 2024-02-26
JP2024508334A5 true JP2024508334A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=80819670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553354A Pending JP2024508334A (ja) 2021-03-03 2022-03-03 家族性高カイロミクロン血症症候群を治療するための方法

Country Status (10)

Country Link
US (1) US20240165093A1 (cg-RX-API-DMAC7.html)
EP (1) EP4301361A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024508334A (cg-RX-API-DMAC7.html)
KR (1) KR20230153375A (cg-RX-API-DMAC7.html)
AU (1) AU2022231007A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016943A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208189A1 (cg-RX-API-DMAC7.html)
IL (1) IL305191A (cg-RX-API-DMAC7.html)
MX (1) MX2023010297A (cg-RX-API-DMAC7.html)
WO (1) WO2022187463A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023000808A2 (pt) 2020-07-29 2023-02-07 Amryt Pharmaceuticals Inc Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
PT1725234E (pt) 2004-03-05 2013-03-04 Univ Pennsylvania Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição

Similar Documents

Publication Publication Date Title
Grote Beverborg et al. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
EP3435996B1 (en) Elafibranor for use in the treatment of primary biliary cholangitis
CN110520125A (zh) 治疗肝病的方法
Yampolsky et al. Augmentation of myocardial If dysregulates calcium homeostasis and causes adverse cardiac remodeling
JP7830313B2 (ja) アルコール性肝炎の処置
US11331292B2 (en) Methods of treatment of cholestatic diseases
US12310935B2 (en) Methods of treatment of cholestatic diseases
JP2023501457A5 (cg-RX-API-DMAC7.html)
JP7756126B2 (ja) 脂肪性肝疾患の治療薬
Nakayama et al. Dilated cardiomyopathy with eosinophilic granulomatosis with polyangiitis in which active myocardial inflammation was only detected by endomyocardial biopsy
JP2017519726A (ja) リポジストロフィー治療用脂肪酸胆汁酸複合体
US20250281507A1 (en) Methods of treating nephrotic syndrome
JP2024508334A (ja) 家族性高カイロミクロン血症症候群を治療するための方法
Sun et al. Jinxinkang Granule Preserves Myocardial Function by Suppressing Cardiac Senescence Through the cGAS-STING Axis in a Pressure Overload Mouse Model of Heart Failure
JP2020533353A (ja) アルコール性肝炎の治療のためのil−1b結合抗体の使用
WO2026107045A1 (en) Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension
WO2025224044A1 (en) Methods of treatment of primary biliary cholangitis
CN110099686B (zh) 非酒精性脂肪性肝病的治疗
AU2024329780A1 (en) Elafibranor for use in the treatment of primary biliary cholangitis
HK40002034A (en) Elafibranor for use in the treatment of primary biliary cholangitis
HK40002034B (en) Elafibranor for use in the treatment of primary biliary cholangitis
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
HK40012462A (en) Treatment of nonalcoholic fatty liver disease